Vistaril

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vistaril

Quick Facts: Vistaril (Hydroxyzine)

Property Description
Active Ingredient Hydroxyzine (INN)
Form Capsule, Oral Suspension, Tablet, Injection
Pharmacological Class First-generation Antihistamine; Anxiolytic
General Purpose Reducing tension and relieving itching
Origin Synthetic Compound

What Type of Medicine Is Vistaril and Its Primary Classification?

Vistaril is the prescription-only trade name for the synthetic pharmaceutical agent, Hydroxyzine, which is a piperazine derivative. The medication holds a unique dual classification, serving as both a potent first-generation antihistamine and an anxiolytic (tranquilizer). This dual functionality arises because the substance readily crosses the blood-brain barrier. This characteristic enables a significant central nervous system (CNS) effect, which provides its tranquilizing action alongside its primary anti-allergic function. This profile is clinically recognized for its efficacy in managing states of generalized anxiety, a property supported by pharmacological studies. This confirms that the medication can help reduce feelings of anxiety and promote general calmness.

Composition and Available Pharmaceutical Forms

Vistaril is a single-entity product where Hydroxyzine is the sole active ingredient, most commonly presented as the pamoate salt for oral preparations. A differentiating feature of the Vistaril brand is its historical and primary availability in the distinctive capsule form, alongside the oral suspension (liquid) and solutions prepared for parenteral administration via intramuscular (IM) injection. The availability of multiple preparations allows for targeted administration, such as the oral route for managing general conditions or the IM route for rapid action in a clinical setting.

General Purpose and Core Therapeutic Benefit

The primary general purpose of Vistaril is to leverage its potent sedative properties to reduce psychological tension and apprehension in various settings. This action is commonly applied in scenarios where temporary anxiety relief is necessary, such as during periods of acute stress. Furthermore, the drug’s capacity to block H1 histamine receptors directly contributes to its secondary, but crucial, general purpose: effectively relieving symptoms of severe pruritus (itching) associated with allergic skin conditions.

Regulatory References

  1. NIH LiverTox: Hydroxyzine

What side effects are possible with Vistaril?

Possible Side Effects and Safety Information

The safety profile for Vistaril (hydroxyzine) is defined by official regulatory documents detailing both common, expected adverse reactions and specific serious cardiovascular risks. Side effects are classified based on their frequency and the system-organ class affected.

Documented Adverse Reactions

The most frequently reported adverse reactions are related to the drug's properties as a Central Nervous System (CNS) depressant and an anticholinergic agent. Drowsiness (somnolence) is the most common effect, which is often described in regulatory labeling as transitory and may lessen with continued use. Other common effects include dry mouth (xerostomia), fatigue, and headache.

Less common or post-marketing reported effects fall under systems such as the CNS (e.g., confusion, involuntary motor activity, tremor), Gastrointestinal (e.g., constipation, nausea), and Renal (e.g., urinary retention).

Serious Safety Risks and Contraindications

The official labeling emphasizes the risk of serious cardiac adverse reactions. These include the potential for QT interval prolongation and the life-threatening ventricular arrhythmia, Torsade de Pointes (TdP), with reported cases of sudden death and cardiac arrest. Consequently, the medication is contraindicated in individuals with a known history of QT prolongation or uncorrected risk factors for it (such as significant electrolyte imbalance or bradycardia). Concomitant use with other drugs known to prolong the QT/QTc interval is strictly prohibited.

Population-Specific Safety Statements

Safety constraints are noted for vulnerable patient groups. Use is not recommended in older adults (elderly) due to a greater risk of adverse effects like confusion. Dose reduction is required for patients with renal or hepatic impairment. Furthermore, the drug is contraindicated in early pregnancy and in nursing mothers.

Overdose and Emergency Response

Overdose and When to Seek Help: Vistaril (Hydroxyzine)

This section outlines the officially documented manifestations of Vistaril (hydroxyzine) overdose and the required emergency actions, based strictly on government regulatory documents.


Documented Overdose Manifestations and Severe Outcomes

Overdosage is most commonly characterized by hypersedation, along with other signs such as convulsions, stupor, nausea, and vomiting. Of greater concern, severe outcomes include the potential for Central Nervous System (CNS) depression and serious cardiovascular effects.

  • Cardiotoxicity: Overdose carries a risk of QT prolongation and a specific life-threatening arrhythmia called Torsade de Pointes (TdP).

Required Emergency Actions

Immediate medical attention is required if signs or symptoms associated with cardiac arrhythmia occur, and use of Vistaril must be stopped. Due to the cardiac risk, ECG monitoring is recommended in cases of suspected overdose.

Officially Described Supportive Measures:

Procedure Requirement Note
Antidote No specific antidote exists. Management is supportive.
Decontamination Inducing vomiting or immediate gastric lavage is recommended. Applies if vomiting has not occurred spontaneously.
Hypotension Managed with IV fluids and vasopressors. Epinephrine must not be used as Hydroxyzine counteracts its effects.
CNS Counteraction Caffeine and Sodium Benzoate Injection, USP, may be used to counteract severe CNS depression.

Population-Specific Considerations

Official labeling notes that elderly patients should be observed closely and generally started on low doses due to decreased drug elimination and increased risk of adverse reactions.

Therapeutic Uses of Vistaril

Vistaril (Hydroxyzine) is generally applied across domains where additional symptomatic support is needed to manage heightened patient distress, including the relief of anxiety and managing symptoms of severe allergic itching. The medication is applied for symptomatic relief across several therapeutic domains.

Its uses are considered relevant in four key areas: symptomatic relief of anxiety and tension, management of pruritus due to allergic conditions like chronic urticaria and dermatoses, procedural support, and the management of nausea and vomiting.


Managing Acute Anxiety, Nervousness, and Tension

Vistaril is commonly used to help with symptoms related to heightened physiological activity and psychological tension, including nervousness, apprehension, and excessive worrying. The application is relevant when supportive symptom management is appropriate, and it contributes to easing the overall symptom load by reducing distress.


Supporting Relief for Severe Allergic Itching (Pruritus)

The medication is relevant for easing symptoms related to inflammatory or irritative states, such as severe pruritus (itching). Offering supportive relief when symptoms interfere with routine activities, it contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Severe Itching

Use Case Symptom Axis Patient Benefit
Chronic Urticaria Inflammatory/Irritative States Supports maintaining functional stability
Atopic Dermatoses Symptoms that become more disruptive Helps patients cope more steadily
Acute Allergic Itching Symptoms that interfere with daily functioning Contributes to improved comfort

Adjunctive Use for Procedural Support and Nausea Control

The drug is applicable within clinical settings that involve acute or disruptive symptom patterns. It is used in settings marked by temporary physiological imbalance to support the management of agitation before procedures and is applied in addressing symptoms of nausea and vomiting. This use assists with maintaining functional stability and supports the patient during difficult episodes by easing distress and is relevant for easing acute post-procedural discomfort.

Eligibility and Restrictions for Use

Vistaril (hydroxyzine) eligibility is strictly defined by government regulatory authorities based on cardiac risk, hypersensitivity, physiological states, and organ function. The official labeling identifies specific population groups for whom use is prohibited or restricted.

Contraindicated Populations

Use is contraindicated (prohibited) for patients with a known prolonged QT interval due to cardiac risk, and for those with known hypersensitivity to hydroxyzine or its derivatives like cetirizine or levocetirizine. The medicine is also contraindicated for women in early pregnancy and for breastfeeding women.

Restricted and Conditional Use

Adults and children 6 years of age and older are generally approved for labeled uses. However, use is restricted in several groups based on pharmacokinetic limitations:

  • Older Adults (Geriatric): Regulatory documents specify a maximum daily dose limit of 50 mg.
  • Organ Function Impairment: Patients with moderate or severe renal impairment must have their total daily dosage reduced by 50%, and those with hepatic impairment by 33%. Use is also subject to formal caution in patients with risk factors for QT prolongation, such as electrolyte imbalances or pre-existing heart disease.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Vistaril

Interaction scope

The official interaction profile of Vistaril (Hydroxyzine) is defined by its effects on the central nervous system and its metabolism through hepatic enzymes.

Scope Element Official Regulatory Information
Medicinal product categories with documented interactions: CNS Depressants; QT-prolonging agents; CYP3A4/5 Inhibitors; Anticholinergic drugs.
Specific interacting medicines (if explicitly listed): Cimetidine; Meperidine; Barbiturates; Cetirizine hydrochloride; Levocetirizine hydrochloride.
Mechanistic basis of interactions (only if stated in label): Potentiation (Pharmacodynamic); Inhibition of Cytochrome P450 3A4/5 (Pharmacokinetic); Inhibition of Cytochrome P450 2D6 (Pharmacokinetic); Increased plasma concentration (Exposure-Altering).
Timing-based interaction rules (if applicable): None explicitly documented as a mandatory time separation requirement.
Population-specific interaction notes (if applicable): Elderly patients are noted for reduced elimination, requiring cautious administration or avoidance.

Interaction classifications (high-level)

Classification Element Official Regulatory Information
Interaction severity classification (as defined in official documents): Contraindicated Combinations (QT-prolongers, CYP3A4/5 Inhibitors); Use-with-Caution Combinations (CNS Depressants); Avoided Substances (Alcohol, Grapefruit).

Official interaction statements:

  • Co-administration with other CNS Depressants results in the potentiation of effects.
  • The medication is formally contraindicated for co-administration with other products known to prolong the QT interval.
  • Strong CYP3A4/5 Inhibitors are contraindicated due to the expected increase in plasma concentration of hydroxyzine.
  • The effect of alcohol may be increased, and Grapefruit products should be avoided.

Connection to the overall interaction profile (2–4 sentences):

Regulatory documents establish the interaction structure through two core mechanisms: the risk of additive cardiac events from pharmacodynamic effects and the risk of heightened systemic exposure due to metabolic inhibition. Restrictions formally prohibit combinations that lead to QT prolongation or disrupt the primary CYP3A4/5 metabolic pathway. The profile includes explicit warnings for substances and populations where reduced clearance or additive effects are officially documented.

Mechanism of Action

How Vistaril Works

Hydroxyzine functions primarily by engaging the H1 histamine receptor. The molecule acts as an inverse agonist at this receptor, which is expressed in both peripheral tissues and the central nervous system. This specific interaction type modulates the baseline constitutive activity of the H1 receptor.

This receptor modulation results in a reduced state of both peripheral and central histamine activity by decreasing receptor signaling below basal levels. This change alters the intracellular downstream signaling cascade typically initiated by histamine binding, affecting cellular responses related to the release of inflammatory mediators.

Hydroxyzine also exhibits additional activity at other neurotransmitter systems. It possesses anticholinergic properties via antagonism at muscarinic acetylcholine receptors ( M1-5). Furthermore, its major metabolite, cetirizine, contributes to the mechanism by inhibiting 5- HT2 A receptors, thereby modulating specific serotonergic pathways. This overall mechanism is characterized by multi-receptor engagement.

Dosage and Administration Information

How to Use Vistaril: Administration Guidelines

Vistaril (hydroxyzine) is administered either orally or by intramuscular (IM) injection. The oral route, utilizing capsules, tablets, or liquid suspension, is standard for non-acute administration. The injectable form is strictly reserved for the IM route, used only when immediate action is necessary or the oral route is not feasible, and must never be injected subcutaneously, intra-arterially, or intravenously. If treatment begins with the IM route, a transition to oral dosing should occur as soon as possible.


Standard Dosing and Frequency

Oral administration is typically in divided doses, three or four times daily, taken with or without food. For anxiety relief, adult doses generally range from 50 mg to 100 mg per dose. For the management of pruritus (itching), administration often starts at 25 mg and may be adjusted up to 100 mg per day.

Indication Adult Dose Range (Oral) Frequency Pattern
Anxiety Relief 50 mg to 100 mg per dose Divided doses, 3 to 4 times daily
Pruritus Management 25 mg to 100 mg total daily Divided doses, 3 to 4 times daily

Population-Specific Dosing Adjustments

Dosage adjustments are required for specific patient groups. For older adults, the starting dose should be at the lower end of the range, and the maximum total daily oral dose is limited to 50 mg. For patients with moderate to severe renal impairment, the total daily dose should be reduced by 50%. A 33 % reduction in the total daily dose is required for patients with hepatic impairment.

Recent Clinical Evidence

Evidence for Symptomatic Relief of Anxiety and Tension

The use of Vistaril in conditions characterized by psychological tension was studied in research exploring short-term changes, primarily through Randomized Controlled Trials (RCTs). These studies mostly included adult outpatients diagnosed with Generalized Anxiety Disorder (GAD). Research examined outcomes related to physiological strain or stress, tracking how symptoms change over time using tools like the Hamilton Rating Scale for Anxiety (HAM-A).

Findings describe patterns observed in studies related to changes in anxiety scale scores over short periods. However, systematic reviews evaluating the evidence suggest that the overall certainty remains low in some comparisons, and methodological issues, such as a high risk of bias, were observed in some studies.


Evidence for Pruritus (Itching) Management in Allergic Conditions

Vistaril was evaluated in studies examining its impact on severe itching, or pruritus, linked to allergic conditions such as chronic urticaria. Research includes RCTs and observational studies, focusing on outcomes linked to inflammatory or irritative states. Studies monitored patient-reported outcomes describing perceived discomfort and changes in sleep disturbance caused by itching.

Overall findings describe group patterns of itching severity changes during the study periods, but systematic reviews note that evidence quality varies across comparisons against newer treatments due to study heterogeneity.


Evidence for Adjunctive Use in Procedural Support

The role of Vistaril as a pre-anesthetic adjunct was evaluated in studies monitoring preoperative tension and apprehension in patients undergoing surgical procedures. This evidence stems primarily from older clinical studies and pharmacology trials, limiting modern comparative data.


Long-Term Studies and Follow-Up Duration

The duration of most controlled trials for Vistaril was observed in short time intervals, typically lasting up to three months. Systematic research specifically exploring long-term effects (beyond four months) are not fully established in the regulatory record.


Evidence in Special Patient Populations

Research has explored outcomes in general populations; however, data remain insufficient for certain groups. Specifically, there is limited information for long-term outcomes in older adults, and subgroup findings for patients with complex comorbid conditions are often uncertain within the existing research base.


Key Uncertainties and Research Gaps

Overall, the research highlights that evidence quality varies across studies. A significant gap remains in data covering follow-up durations were limited, especially the need for more systematic research exploring effectiveness for long-term use extending beyond four months. Comparative evidence against modern treatments is also lacking in several areas.

Frequently Asked Questions (FAQ)

Common questions about Vistaril (FAQ)

Q: How long does the effect of Vistaril typically last?

A: Official product information describes the duration of the main clinical effects as typically lasting for 4 to 6 hours after oral administration. This relates to the drug's activity in the body during that time frame.

Q: Can Vistaril cause trouble sleeping (insomnia) for some people?

A: Insomnia (trouble sleeping) is not listed as a common documented side effect in regulatory documents. The drug's sedative properties are noted in its mechanism of action, which may relate to its use in conditions involving anxiety and tension.

Q: Can Vistaril be taken at the same time as cold or allergy medicine?

A: Regulatory warnings state that co-administration with certain over-the-counter cold and allergy medicines is cautioned against. This is because these products often contain other ingredients that can increase the risk of severe drowsiness and sedation when taken with Vistaril.

Q: Does Vistaril affect blood pressure readings?

A: Low blood pressure, also known as hypotension, is listed as a potential serious adverse reaction in the safety label. This effect is often noted in case reports involving overdose.

Q: Does Vistaril interact with SSRI antidepressants?

A: Official documentation notes that combining Vistaril with specific SSRIs known to prolong the QT interval requires caution due to the risk of a serious heart rhythm issue. This risk is clearly defined in the interaction profile.

Q: What does 'antihistamine' mean in the context of Vistaril?

A: Vistaril is classified as a potent antihistamine, which means it works by blocking the action of histamine. Histamine is a chemical the body releases during an allergic reaction, and blocking it helps reduce allergic symptoms like itching.

Q: What is the difference between Vistaril capsules and tablets?

A: Vistaril is typically the branded capsule form, containing the pamoate salt of the active ingredient. The generic hydroxyzine is often available as the tablet form, which contains the hydrochloride salt. Both forms are approved by the FDA for the same indications.

Q: Is Vistaril considered a habit-forming medicine?

A: Vistaril is not classified as a controlled substance by the DEA and is not generally considered addictive or habit-forming.

Q: How quickly does Vistaril start to work after taking it?

A: According to official pharmacokinetic data, the clinical effects of the medication are generally noted within 15 to 30 minutes after oral administration.

Q: Can Vistaril be used for long periods of time?

A: The effectiveness of Vistaril for long-term use, meaning more than 4 months, has not been assessed by systematic clinical studies. Regulatory documents indicate that the use should be reassessed periodically.

Q: Does Vistaril affect driving or operating machinery?

A: Official warnings state that caution is advised regarding driving a car or operating dangerous machinery due to the risk of drowsiness. This is a common and expected side effect of the drug.

Q: Can Vistaril interact with common pain relievers like ibuprofen?

A: No direct interaction between hydroxyzine and common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen has been documented in the official regulatory product labeling.

Q: Is there a maximum time someone is generally supposed to use Vistaril?

A: There is no mandatory maximum time limit for using Vistaril cited in regulatory documents. However, clinical studies supporting the drug's effectiveness do not extend beyond four months.

Q: Do food or meals impact how Vistaril works?

A: Regulatory information states that Vistaril can be taken with or without food. Taking it with food may be suggested if the medication causes an upset stomach.

Q: Does Vistaril cause weight gain?

A: Weight gain is not listed among the most common or officially documented adverse reactions in the FDA product labeling.

Q: Is it possible to take Vistaril just 'as needed'?

A: Official dosing information describes that the medication can be prescribed to be taken on an 'as needed' (PRN) basis for some labeled indications.

Q: What kind of studies have been done on Vistaril?

A: Studies have included Randomized Controlled Trials (RCTs) and older clinical trials. This research has primarily focused on the symptomatic relief of anxiety, management of pruritus (itching), and its use as a pre-anesthetic sedative.

Q: What happens if a dose of Vistaril is missed?

A: If a dose is missed, patient instructions recommend taking it as soon as it is remembered. However, if it is closer to the time for the next dose, the recommendation is to skip the missed dose rather than taking a double dose.

Q: Does Vistaril have any known interactions with herbal supplements?

A: Regulatory guidance advises consulting a healthcare provider regarding specific herbal supplements, especially those that may interfere with liver enzymes involved in the drug's metabolism.

Q: Can I use Vistaril if I have glaucoma?

A: Vistaril is cautioned for patients with glaucoma. Due to its anticholinergic effects, the drug can potentially worsen certain types of glaucoma, such as acute angle-closure glaucoma.

Q: Is Vistaril associated with any long-term effects on memory?

A: While the drug’s post-marketing reports list adverse reactions like confusion and hallucination, the official product labeling does not specifically document long-term effects on memory.

Q: Can a person develop a tolerance to Vistaril over time?

A: Studies indicate it is possible for a person to develop a tolerance to the effects of Vistaril, which may result in a reduced level of effectiveness over time.

Q: Is there a risk of having an allergic reaction to Vistaril?

A: Yes. Official safety information cautions regarding the risk of a severe allergic reaction and a serious, rare skin reaction, known as Acute Generalized Exanthematous Pustulosis (AGEP), requiring immediate medical attention.

Q: Why is Vistaril sometimes used before a procedure?

A: Official documents describe its use as a pre-anesthetic adjunct. This is primarily because of its sedative properties, which help to reduce psychological tension and apprehension in patients undergoing procedures.

Q: What is the main purpose of Vistaril's safety label?

A: The main purpose of the official safety label is providing mandated information to patients and healthcare professionals detailing the drug's proper use, dosing, documented risks, and side effects.

Q: What are the limitations of the current research on Vistaril?

A: Research limitations cited in regulatory documents include a lack of systematic clinical data extending beyond four months of use. There is also limited comparative evidence against modern treatments in several areas.

Q: Are there specific times of day Vistaril is usually taken?

A: Dosing is typically prescribed in divided doses, three or four times daily. Due to the high risk of drowsiness, taking the largest dose at bedtime may be a consideration.

Q: Does Vistaril interact with opioid pain medications?

A: Opioid pain medications are Central Nervous System (CNS) depressants. Combining Vistaril with them may result in a potentiation of effects, potentially leading to severe drowsiness or sedation.

How should Vistaril be stored and disposed of?

How to Store and Dispose of Vistaril (Hydroxyzine Pamoate)

Storage conditions for Vistaril are defined by regulatory requirements to ensure product stability and safety.

Storage Conditions

Vistaril capsules and oral suspension must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F). The capsules must also be protected from moisture and dispensed in a tight, light-resistant container.

Liquid forms must be protected from freezing. The oral suspension must be shaken vigorously until completely resuspended before use.

All forms of the medication must be stored out of the sight and reach of children.

Disposal Instructions

Unused or outdated Vistaril must not be kept and should be disposed of in accordance with applicable local and national regulations. Patients are directed to ask a pharmacist or healthcare professional for guidance on the proper disposal procedure. Disposal instructions prohibit discharge into drains, water courses, or onto the ground.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vistaril found in:

A-Z Index: